13/05/2019 14:21:16

DEADLINE TODAY: Rosen Law Firm Reminds Corcept Therapeutics Incorporated Investors of Important May 13th Deadline in Securities Class Action Lawsuit - CORT

NEW YORK, May 13, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Corcept Therapeutics Incorporated (NASDAQ: CORT) from August 2, 2017 through February 5, 2019, inclusive (the “Class Period”) of the important May 13, 2019 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Corcept investors under the federal securities laws.

To join the Corcept class action, go to https://www.rosenlegal.com/cases-register-1536.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Corcept had improperly paid doctors to promote its drug, Korlym; (2) Corcept aggressively promoted Korlym for off-label uses; (3) Corcept’s sole specialty pharmacy was a related party; (4) Corcept artificially inflated its revenue and sales using illicit sales practices through a related party; (5) such practices were reasonably likely to lead to regulatory scrutiny; and (6) as a result, defendants’ positive statements about Corcept’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 13, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to https://www.rosenlegal.com/cases-register-1536.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has secured hundreds of millions of dollars for investors.

Contact Information:

      Laurence Rosen, Esq.

      Phillip Kim, Esq.

      The Rosen Law Firm, P.A.

      275 Madison Avenue, 34th Floor

      New York, NY  10016

      Tel: (212) 686-1060

      Toll Free: (866) 767-3653

      Fax: (212) 202-3827

      lrosen@rosenlegal.com

      pkim@rosenlegal.com

      cases@rosenlegal.com

      www.rosenlegal.com

Related content
28 Aug - 
Corcept Therapeutics Announces Allowance of Additional ..
01 Aug - 
Corcept Therapeutics Announces Second Quarter 2019 Fina..
28 May - 
Corcept Therapeutics to Present Data from Phase 1/2 Tri..
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
UPDATE - Yoko Ono and John Lennon Educational Tour Bus “Imagine A City With No Gun Violence!”
2
Translate Bio Announces Pricing of Public Offering of Common Stock
3
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SAExploration Holdings, Inc. - SAEX
4
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Pluralsight, Inc. - PS
5
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

Related stock quotes

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
18 September 2019 17:22:57
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190829.2 - EUROWEB1 - 2019-09-18 18:22:57 - 2019-09-18 17:22:57 - 1000 - Website: OKAY